UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

Annals of oncology, 2020-03, Vol.31 (3), p.412-421

2020

Volltextzugriff (PDF)

Local Therapy for Metastatic Salivary Adenoid Cystic Carcinoma: A Surveillance, Epidemiology, and End Results and National Cancer Data Base Analysis

International journal of radiation oncology, biology, physics, 2016-03, Vol.94 (4), p.953-953

2016

Volltextzugriff (PDF)

Induction Chemotherapy Predicts Cumulative Radiation Dose and Fails to Improve Survival in Advanced Head and Neck Cancer, a National Cancer Data Base Analysis

International journal of radiation oncology, biology, physics, 2016-03, Vol.94 (4), p.874-875

2016

Volltextzugriff (PDF)

Survival Impact of Local Therapy for Thyroid Carcinoma: A Surveillance, Epidemiology, and End Results Analysis

International journal of radiation oncology, biology, physics, 2016-03, Vol.94 (4), p.951-951

2016

Volltextzugriff (PDF)

Does Age Matter? Survival Outcomes With the Addition of Concurrent Chemotherapy for Elderly Head and Neck Cancer Patients Undergoing Definitive Radiation Using the National Cancer Data Base

International journal of radiation oncology, biology, physics, 2016-03, Vol.94 (4), p.871-871

2016

Volltextzugriff (PDF)

Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequentBAP1,PIK3CA, and other actionable genomic alterations

Annals of oncology, 2017-04, Vol.28 (4), p.748-753

2017

Volltextzugriff (PDF)

A Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent/Metastatic (R/M) Head-and-Neck Squamous Cell Carcinoma

International journal of radiation oncology, biology, physics, 2014-02, Vol.88 (2), p.511-511

2014

Volltextzugriff (PDF)

573P Panorama of genomic RET alterations (GA) in the major subtypes of thyroid carcinomas (TC)

Annals of oncology, 2021-09, Vol.32, p.S623-S623

2021

Volltextzugriff (PDF)

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Annals of oncology, 2021-06, Vol.32 (6), p.787-800

2021

Volltextzugriff (PDF)

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of oncology, 2022-11, Vol.33 (11), p.1168-1178

2022

Volltextzugriff (PDF)

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer

Oncogene, 2016-01, Vol.35 (3), p.290-300

2016

Volltextzugriff (PDF)

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies

Annals of oncology, 2017-10, Vol.28 (10), p.2539-2546

2017

Volltextzugriff (PDF)

604P Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status

Annals of oncology, 2023-11, Vol.34, p.S1708-S1709

2023

Volltextzugriff (PDF)

903P AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes

Annals of oncology, 2023-10, Vol.34, p.S575-S576

2023

Volltextzugriff (PDF)

919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)

Annals of oncology, 2020-09, Vol.31, p.S663-S663

2020

Volltextzugriff (PDF)

1917P Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial

Annals of oncology, 2020-09, Vol.31, p.S1086-S1087

2020

Volltextzugriff (PDF)

LBA67 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy

Annals of oncology, 2021-09, Vol.32, p.S1343-S1343

2021

Volltextzugriff (PDF)

904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort

Annals of oncology, 2021-09, Vol.32, p.S803-S804

2021

Volltextzugriff (PDF)

MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S89-S90

2022

Volltextzugriff (PDF)

1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)

Annals of oncology, 2022-09, Vol.33, p.S1083-S1084

2022

Volltextzugriff (PDF)

1918P Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)

Annals of oncology, 2020-09, Vol.31, p.S1087-S1087

2020

Volltextzugriff (PDF)

Evaluating PET-Based Functional Imaging Changes in the Heart after Thoracic Chemo-Radiation

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.S235-S235

2019

Volltextzugriff (PDF)

Targeted therapies for ROS1-rearranged non-small cell lung cancer

Drugs of Today, 2019-10, Vol.55 (10), p.641-652

2019

Volltextzugriff (PDF)

Update on multikinase inhibitor therapy for differentiated thyroid cancer

Drugs of Today, 2018-09, Vol.54 (9), p.535-545

2018

Volltextzugriff (PDF)

Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer

Drugs of today (Barcelona, Spain : 1998), 2013-09, Vol.49 (9), p.523

2013

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(41)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

Local Therapy for Metastatic Salivary Adenoid Cystic Carcinoma: A Surveillance, Epidemiology, and End Results and National Cancer Data Base Analysis

Induction Chemotherapy Predicts Cumulative Radiation Dose and Fails to Improve Survival in Advanced Head and Neck Cancer, a National Cancer Data Base Analysis

Survival Impact of Local Therapy for Thyroid Carcinoma: A Surveillance, Epidemiology, and End Results Analysis

Does Age Matter? Survival Outcomes With the Addition of Concurrent Chemotherapy for Elderly Head and Neck Cancer Patients Undergoing Definitive Radiation Using the National Cancer Data Base

Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequentBAP1,PIK3CA, and other actionable genomic alterations

A Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent/Metastatic (R/M) Head-and-Neck Squamous Cell Carcinoma

573P Panorama of genomic RET alterations (GA) in the major subtypes of thyroid carcinomas (TC)

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies

604P Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status

903P AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes

919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)

1917P Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial

LBA67 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy

904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort

MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)

1918P Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)

Evaluating PET-Based Functional Imaging Changes in the Heart after Thoracic Chemo-Radiation

Targeted therapies for ROS1-rearranged non-small cell lung cancer

Update on multikinase inhibitor therapy for differentiated thyroid cancer

Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer

Suchergebnisse filtern